BioAdaptives Inc. — News

Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new Xcellara™ cellular wellness line, will take place later this week. Customers and distributors will soon be able to place orders directly through products.xcellara.com.

accessnewswire.com - 2026-08-03 08:00:00

Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, announced it has successfully retired its largest convertible commercial investor.

accessnewswire.com - 2026-07-30 08:30:00

LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront operations and direct-to-consumer (DTC) marketing footprint for its flagship cognitive performance line, MyndSystem™. The MyndSystem™ is a WADA-compliant, stimulant-free cognitive enhancement suite designed to support 24-hour brain performance.

accessnewswire.com - 2026-07-29 13:15:00

LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.

globenewswire.com - 2026-07-23 07:30:00

Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas

globenewswire.com - 2026-07-16 08:30:00

The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology

globenewswire.com - 2026-07-15 08:30:00

Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments

globenewswire.com - 2026-06-25 14:48:00

Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the day. Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the day.

globenewswire.com - 2026-05-20 16:15:00